- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | OncoZenge AB: OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds | 238 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1... ► Artikel lesen | |
| 17.07. | OncoZenge AB: OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds | 231 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1... ► Artikel lesen | |
| 07.07. | OncoZenge AB: OncoZenge AB Announces Enrollment of First Patient in Pivotal Phase III BEAM-Pain Trial of BupiZenge | 1.074 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announces that the first patient has been... ► Artikel lesen | |
| 03.07. | OncoZenge AB: OncoZenge Extends the Payment Deadline for Subscription Proceeds | 223 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the subscription proceeds of approximately SEK 15.1 million in... ► Artikel lesen | |
| 02.06. | OncoZenge AB: OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici | 210 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that the second milestone payment has been received from the Company's licensee, Molteni Farmaceutici.
The company announced on March... ► Artikel lesen | |
| ONCOZENGE Aktie jetzt für 0€ handeln | |||||
| 27.05. | OncoZenge AB: Bulletin From The Annual General Meeting Of OncoZenge | 198 | GlobeNewswire (Europe) | At the annual general meeting ("AGM") of OncoZenge AB (publ) held on 27 May 2026, the following principal resolutions were adopted, in accordance with the proposals submitted by the Board of Directors... ► Artikel lesen | |
| 26.05. | OncoZenge AB: OncoZenge Receives European Regulatory Approval to Start Pivotal Phase III Trial of BupiZenge | 737 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announced that it has received regulatory... ► Artikel lesen | |
| 26.05. | OncoZenge AB: OncoZenge AB Interim Report January 1 - March 31, 2026 | 216 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the first quarter of 2026. The company reports progress with European authorities expecting regulatory approval... ► Artikel lesen | |
| 22.05. | OncoZenge AB: OncoZenge enters into a loan agreement of SEK 2 million with Linc AB | 161 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") has today entered into an agreement regarding bridge financing of SEK 2 million through a loan provided by one of the Company's largest shareholders... ► Artikel lesen | |
| 19.05. | OncoZenge AB: OncoZenge Provides Regulatory Update on BupiZenge Phase III Trial | 247 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that it has received written notification from European authorities regarding the ongoing assessment of its Clinical Trial Application... ► Artikel lesen | |
| 28.04. | OncoZenge AB: OncoZenge Receives Conditional Acceptance for the Clinical Phase III Trial ('BEAM-Pain') of BupiZenge from European Authorities | 590 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announces that it has received conditional... ► Artikel lesen | |
| 02.04. | OncoZenge AB: OncoZenge Confirms Submission of Responses to EMA on the BupiZenge Phase III Trial (BZ003) | 149 | GlobeNewswire (Europe) | OncoZenge AB (publ), OncoZenge or "the Company", developing innovative treatments for oral pain management, today announced the complete submission of responses to European authorities' Requests for... ► Artikel lesen | |
| 01.04. | OncoZenge AB: OncoZenge Reports Positive Stability Results for BupiZenge as Key Enabler for the Upcoming Phase III Trial | 151 | GlobeNewswire (Europe) | OncoZenge AB (publ), a pharmaceutical company developing innovative treatments for oral pain management, today announced that the three-month stability study results for its BupiZenge lozenge are within... ► Artikel lesen | |
| 26.02. | OncoZenge AB: OncoZenge AB Year-end Report January 1 - December 31, 2025 | 211 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced its full year report for 2025, a year of significant progress culminating in the submission of the Phase III Clinical Trial Application... ► Artikel lesen | |
| 12.02. | OncoZenge AB: OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical | 303 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the third tranche of investment capital from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd. (the "Investor").
The investment... ► Artikel lesen | |
| 02.02. | OncoZenge AB: OncoZenge AB Appoints Dr. Marie-Louise Fjällskog as Chief Medical Officer | 364 | GlobeNewswire (Europe) | OncoZenge AB (publ) (the "Company"), a clinical-stage pharmaceutical company developing innovative treatments for oral pain, today announced the appointment of Dr. Marie-Louise Fjällskog, MD, PhD, as... ► Artikel lesen | |
| 30.01. | OncoZenge AB: OncoZenge AB Reports Positive Initial Stability Results for the BupiZenge Technology Batch, Advancing Toward Clinical Trials | 210 | GlobeNewswire (Europe) | OncoZenge AB (publ), a pharmaceutical company developing innovative treatments for oral pain management, today announced that the one-month stability study results for its BupiZenge lozenge technology... ► Artikel lesen | |
| 22.01. | OncoZenge AB: OncoZenge enters into convertible loan agreement with Linc AB and gives an update on the payment of subscription proceeds | 557 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or the "Company") has today entered into an agreement for a bridge financing solution of SEK 5 million, via a convertible note with Linc AB ("Linc") to be repaid upon... ► Artikel lesen | |
| 22.01. | OncoZenge AB receives observation status | 271 | GlobeNewswire | Yesterday, January 21, 2026, OncoZenge AB (the "Company") disclosed a press release with information about uncertainties regarding the payment of the subscription proceeds in a previously announced... ► Artikel lesen | |
| 21.01. | OncoZenge AB: OncoZenge announces uncertainty regarding payment of subscription proceeds and liquidity impact | 331 | GlobeNewswire (Europe) | OncoZenge AB (publ) (the "Company") has just been informed that the strategic investor Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the "Investor") will not be able to pay the subscription proceeds... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 39,775 | -0,91 % | Comeback-Aktie oder Vorsicht? Gerresheimer, Novo Nordisk, American Atomics | Die Aktie von Novo Nordisk ist innerhalb weniger Handelstage um rund 10 % eingebrochen. Damit ist das im April gestartete Comeback der Aktie des Pharmagiganten bis auf Weiteres beendet. Nach enttäuschenden... ► Artikel lesen | |
| ASTRAZENECA | 136,20 | -0,98 % | ANALYSE-FLASH: Jefferies belässt Astrazeneca auf 'Buy' - Ziel 17500 Pence | NEW YORK (dpa-AFX Broker) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca auf "Buy" mit einem Kursziel von 17500 Pence belassen. Die Uhr laufe weiter gegen das Negativszenario bei dem... ► Artikel lesen | |
| CAMURUS | 57,10 | +2,06 % | Camurus AB: Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA | PDUFA target action date set to 18 December 2026LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted... ► Artikel lesen | |
| BAYER | 48,140 | +0,29 % | Bayer bekommt im Glyphosat-Poker mehr Zeit - High Noon am 14. Sepember | Die Entscheidung beim Glyphosat-Vergleich verzögert sich. Doch die Verschiebung könnte Bayer sogar helfen. Am 14. September steht bei dem 7,25-Milliarden-US-Dollar-Deal viel auf dem Spiel für die Leverkusener.... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,220 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 15,090 | 0,00 % | Generate Biomedicines, Inc. - 10-Q, Quarterly Report | ||
| ETON PHARMACEUTICALS | 41,550 | -0,07 % | H.C. Wainwright hebt Kursziel für Eton Pharmaceuticals auf 65 US-Dollar an | ||
| MERCK KGAA | 139,05 | 0,00 % | Opening Bell: Merck, PVA TePla, AppLovin, Western Digital, MercadoLibre, Albemarle | Die Wall Street hat gestern ein gemischtes Bild geboten. Der Dow Jones lieferte Futter für die Bullen und schloss den fünften Tag in Folge in der Gewinnzone. Anders die Techwerte. Der technologielastige... ► Artikel lesen | |
| LB PHARMACEUTICALS | 45,390 | +0,02 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 79,66 | +0,37 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 23,800 | 0,00 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,125 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update | Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST (etripamil) nasal spray Phase 3 registrational trial of etripamil... ► Artikel lesen | |
| PFIZER | 22,895 | +0,28 % | Drei Wege zum Krebsmedikament der Zukunft: BioNTech, Vidac Pharma und Pfizer im Onkologie-Check | Die Onkologie hat sich zum dynamischsten Innovationsfeld der Pharmabranche entwickelt. Dabei wird nicht nach einem Wundermittel gesucht, sondern man ist bestrebt, hochpräzise personalisierte Therapien... ► Artikel lesen | |
| KARDIGAN | 21,920 | +0,64 % | Kardigan, Inc. - 10-Q, Quarterly Report | ||
| APNIMED | 26,450 | -0,73 % | Apnimed, Inc.: Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization... ► Artikel lesen |
Das Unternehmen ONCOZENGE AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,019 (-3,46 %) liegt der Kurs bei 0,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOZENGE AB finden Sie auf Wallstreet Online.